On June 18, 2025, Needham analyst Ami Fadia reiterated a Buy rating for Immuneering (IMRX, Financial). The analyst has maintained a price target of $9.00 USD for the stock, which remains unchanged from the prior assessment.
This rating and price target reaffirms the analyst's positive outlook on Immuneering (IMRX, Financial). The price target suggests the analyst's continued confidence in the company's future performance within the stock market.
Investors interested in Immuneering (IMRX, Financial) should consider this reiterated rating and consistent price target by Needham, as it highlights the anticipated stability and potential growth for the company's stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Immuneering Corp (IMRX, Financial) is $13.25 with a high estimate of $21.00 and a low estimate of $9.00. The average target implies an upside of 628.02% from the current price of $1.82. More detailed estimate data can be found on the Immuneering Corp (IMRX) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Immuneering Corp's (IMRX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
